Disc Medicine Income Statement (2020-2026) | IRON

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Cost of Revenue (Quarter)
Operating items
Research & Development (Quarter)
10.84M13.46M-10.91M7.82M7.71M7.89M10.02M20.18M12.10M14.42M22.57M23.70M23.48M24.68M24.80M27.76M46.32M50.33M46.22M45.90M
Selling, General & Administrative (Quarter)
5.48M5.00M-9.41M2.14M4.30M2.59M5.00M4.95M5.23M4.54M7.15M7.76M7.37M8.17M9.75M12.18M15.09M17.36M20.75M23.62M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
16.32M18.45M-20.33M9.96M12.02M10.48M15.02M25.12M17.33M18.96M29.71M31.46M30.85M32.86M34.55M39.95M61.41M67.70M66.97M69.52M
Operating Income (Quarter)
-16.32M-18.45M20.33M-9.96M-12.02M-10.48M-15.02M-25.12M-17.33M-18.96M-29.71M-31.46M-30.85M-32.86M-34.55M-39.95M-61.41M-67.70M-66.97M-69.52M
EBIT (Quarter)
-16.32M-18.45M20.33M-9.96M-12.02M-10.48M-15.02M-25.12M-17.33M-18.96M-29.71M-31.46M-30.85M-32.86M-34.55M-39.95M-61.41M-67.70M-66.97M-69.52M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.00M0.01M0.04M0.27M0.39M2.37M2.91M4.84M4.68M4.52M4.57M6.36M5.84M6.88M7.06M6.41M7.41M6.89M
Other Non Operating Income (Quarter)
-5.05M0.10M3.39M-0.01M0.01M-0.01M-0.00M-0.01M0.01M0.00M-0.00M0.07M-0.02M-0.00M0.02M
Non Operating Income (Quarter)
-0.01M-0.00M-5.02M0.11M2.44M0.65M1.41M4.86M6.17M-0.00M4.56M0.01M0.00M5.98M6.21M5.48M-17.63M6.07M
Net income details
EBT (Quarter)
-16.44M-18.45M18.18M-9.85M-9.58M-16.15M-11.24M-22.76M-15.92M-14.10M-23.55M-26.94M-26.29M-26.48M-29.28M-33.97M-55.20M-62.22M-60.77M-63.45M
Tax Provisions (Quarter)
0.02M0.02M-0.00M0.01M-0.01M0.11M0.18M0.05M0.10M0.09M
Profit After Tax (Quarter)
-16.45M-18.55M18.08M-9.85M-9.58M-16.15M-11.24M-22.78M-15.95M-14.12M-23.58M-26.95M-26.35M-26.60M-29.46M-34.09M-55.25M-62.32M-60.53M-63.50M
Income from Continuing Operations (Quarter)
-16.44M-18.45M18.18M-9.85M-9.58M-16.15M-11.24M-22.78M-15.95M-14.10M-23.55M-26.95M-26.29M-26.60M-29.46M-33.97M-55.25M-62.32M-60.86M-63.45M
Consolidated Net Income (Quarter)
-16.44M-18.45M18.18M-9.85M-9.58M-16.15M-11.24M-22.78M-15.95M-14.10M-23.55M-26.95M-26.29M-26.60M-29.46M-33.97M-55.25M-62.32M-60.86M-63.45M
Income towards Parent Company (Quarter)
-16.44M-18.45M18.18M-9.85M-9.58M-16.15M-11.24M-22.78M-15.95M-14.10M-23.55M-26.95M-26.29M-26.60M-29.46M-33.97M-55.25M-62.32M-60.86M-63.45M
Net Income towards Common Stockholders (Quarter)
-16.45M-18.45M18.18M-9.85M-9.58M-16.15M-11.24M-22.78M-15.95M-14.12M-23.58M-26.95M-26.35M-26.60M-29.46M-33.97M-55.25M-62.32M-60.86M-63.45M
Additional items
EPS (Basic) (Quarter)
-0.38-0.43-39.58-10.67-10.14-16.82-7.32-1.20-0.74-0.58-0.97-1.09-1.03-0.89-0.98-1.02-1.58-1.77-1.62-1.65
EPS (Weighted Average and Diluted) (Quarter)
-0.38-0.43-39.58-10.67-10.14-16.82-7.32-1.20-0.74-0.58-0.97-1.09-1.03-0.89-0.98-1.02-1.58-1.77-1.62-1.65
Shares Outstanding (Weighted Average) (Quarter)
43.04M39.43M0.88M0.92M43.22M43.26M1.04M18.95M0.20M21.61M22.32M24.81M25.23M29.94M27.61M33.32M35.02M34.52M35.30M38.49M
Shares Outstanding (Diluted Average) (Quarter)
43.04M39.43M0.88M0.92M0.93M0.96M1.04M18.95M0.20M21.61M22.32M24.81M25.65M29.94M27.61M33.32M34.18M35.18M35.30M38.49M
EBITDA (Quarter)
-16.32M-18.45M20.33M-9.96M-12.02M-10.48M-15.02M-25.12M-17.33M-18.96M-29.71M-31.46M-30.85M-32.86M-34.55M-39.95M-61.41M-67.70M-66.97M-69.52M
Interest Expenses (Quarter)
0.12M0.00M2.15M0.07M0.05M0.57M0.90M0.91M0.92M0.88M0.84M
Tax Rate (Quarter)
-0.10%-0.15%0.00%-0.02%0.02%-0.43%-0.60%-0.09%-0.16%-0.14%